A groundbreaking trial in June 2024 revealed that Lenacapavir, a new medicine injected once every six months, was 100% effective in preventing HIV among over 5,000 girls and women in Uganda and South Africa. Currently, the FDA has approved Lenacapavir only for treating HIV resistant to other treatments. However, its producer, Gilead, has made agreements to produce generic versions for HIV prevention in 120 low-income countries. This development aligns with the United Nations’ ambitious goal to end AIDS by 2030, despite the global challenge of over 1 million new HIV infections annually. The key to achieving this goal lies in ensuring access to these innovative medicines.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
